Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15061394 | 0.88 | BCHE (0.37) | PHF8KDM2A | |
| SCHEMBL23703653 | 0.85 | BCHE (0.44) | PHF8KDM2A | |
| SCHEMBL14081818 | 0.80 | MEN1 (0.37) | KMT2AMEN1PHF8KDM2A | |
| SCHEMBL4019745 | 0.79 | PHF8 (0.39) | KMT2AMEN1NPC1RAB9APHF8 | |
| SCHEMBL15973939 | 0.78 | NPC1 (0.31) | NPC1RAB9A | |
| SCHEMBL3297922 | 0.78 | ALDH1A1 (0.46) | KMT2ANPC1RAB9APHF8KDM2A | |
| SCHEMBL1921576 | 0.77 | MEN1 (0.35) | KMT2AMEN1 | |
| SCHEMBL499576 | 0.76 | HDAC6 (0.38) | — | |
| SCHEMBL15684245 | 0.76 | PHF8 (0.54) | NPC1RAB9APHF8KDM2A | |
| SCHEMBL22205611 | 0.75 | LMNA (0.44) | KMT2AMEN1PHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| US-10941138-B2 | Quinoline and isoquinoline derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-03-09 | — | — | US | disclosed |
| US-20200087291-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-19 | — | — | US | disclosed |
| EP-3558965-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115064-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2018-06-28 | — | — | WO | disclosed |
| EP-3339304-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | Laboratorios del Dr. Esteve, S.A. (ES) | 2018-06-27 | — | — | EP | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941138-B2 | Quinoline and isoquinoline derivatives for treating pain and pain related conditions | CACNA1B, SCN2A, CACNA1C | KMT2A 1993/4885MEN1 4032/4885NPC1 701/4885 |
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | KMT2A 3830/4885MEN1 2445/4885NPC1 898/4885 |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | KMT2A 3286/4885MEN1 2794/4885NPC1 656/4885 |
| US-20200087291-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, SCN2A, CACNA1C | KMT2A 1767/4885MEN1 4112/4885NPC1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.